- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07556159
Uno studio che valuta le caratteristiche della malattia e gli esiti nei partecipanti con asma nella pratica clinica di routine (AIRITY)
Uno studio ibrido trasversale e prospettico per valutare le caratteristiche del paziente, il carico della malattia, il controllo della malattia, i fenotipi, gli endotipi e gli esiti in un contesto reale in pazienti con asma
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Trial Transparency email recommended-Toll free for US & Canada
- Numero di telefono: 6 800-633-1610
- Email: Contact-US@sanofi.com
Luoghi di studio
-
-
Alberta
-
Calgary, Alberta, Canada, T3R 1W7
- Reclutamento
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, Canada, N8X 2G1
- Reclutamento
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, Canada, G8T7A1
- Reclutamento
- Investigational Site Number: 124204
-
-
-
-
Brittany Region
-
Brest, Brittany Region, Francia, 29200
- Reclutamento
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, Francia, 34400
- Reclutamento
- Investigational Site Number: 250612
-
Toulouse, Occitanie, Francia, 31059
- Reclutamento
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, Francia, 85000
- Reclutamento
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Francia, 95100
- Reclutamento
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, Francia, 94010
- Reclutamento
- Investigational Site Number: 250609
-
-
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), Germania, 85039
- Reclutamento
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Germania, 53119
- Reclutamento
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, Germania, 09337
- Reclutamento
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, Germania, 24837
- Reclutamento
- Investigational Site Number: 276502
-
-
-
-
-
Niigata, Giappone
- Reclutamento
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, Giappone, 802-0083
- Reclutamento
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, Giappone, 761-8073
- Reclutamento
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, Giappone, 849-8501
- Reclutamento
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Giappone, 113-8431
- Reclutamento
- Investigational Site Number: 392710
-
tabashi City, Tokyo, Giappone, 173-8610
- Reclutamento
- Investigational Site Number: 392709
-
-
-
-
-
Madrid, Spagna, 28034
- Reclutamento
- Investigational Site Number: 724408
-
-
-
-
Alabama
-
Bessemer, Alabama, Stati Uniti, 35022
- Reclutamento
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, Stati Uniti, 85224
- Ritirato
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, Stati Uniti, 85206
- Attivo, non reclutante
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, Stati Uniti, 85254
- Reclutamento
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, Stati Uniti, 85351
- Attivo, non reclutante
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, Stati Uniti, 91107
- Attivo, non reclutante
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, Stati Uniti, 90623
- Attivo, non reclutante
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, Stati Uniti, 90017
- Attivo, non reclutante
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, Stati Uniti, 92663
- Attivo, non reclutante
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, Stati Uniti, 91101
- Attivo, non reclutante
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, Stati Uniti, 91356
- Ritirato
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, Stati Uniti, 94598
- Attivo, non reclutante
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, Stati Uniti, 32701
- Attivo, non reclutante
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, Stati Uniti, 33431
- Attivo, non reclutante
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, Stati Uniti, 33511
- Attivo, non reclutante
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, Stati Uniti, 33467
- Attivo, non reclutante
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, Stati Uniti, 33126
- Attivo, non reclutante
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, Stati Uniti, 33126
- Attivo, non reclutante
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, Stati Uniti, 33130
- Attivo, non reclutante
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, Stati Uniti, 33142
- Attivo, non reclutante
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, Stati Uniti, 33145
- Attivo, non reclutante
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, Stati Uniti, 33155
- Attivo, non reclutante
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, Stati Uniti, 33173
- Attivo, non reclutante
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, Stati Uniti, 33174
- Attivo, non reclutante
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, Stati Uniti, 33186
- Attivo, non reclutante
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, Stati Uniti, 33014
- Attivo, non reclutante
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, Stati Uniti, 33014
- Attivo, non reclutante
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, Stati Uniti, 33014
- Attivo, non reclutante
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, Stati Uniti, 33016
- Attivo, non reclutante
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, Stati Uniti, 33169
- Attivo, non reclutante
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, Stati Uniti, 33406
- Attivo, non reclutante
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, Stati Uniti, 33317
- Attivo, non reclutante
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, Stati Uniti, 34986
- Attivo, non reclutante
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, Stati Uniti, 33321
- Attivo, non reclutante
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, Stati Uniti, 33613
- Attivo, non reclutante
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, Stati Uniti, 33409
- Attivo, non reclutante
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, Stati Uniti, 31904
- Attivo, non reclutante
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60616
- Attivo, non reclutante
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40509
- Attivo, non reclutante
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, Stati Uniti, 21045
- Reclutamento
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, Stati Uniti, 20854
- Attivo, non reclutante
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, Stati Uniti, 59808
- Attivo, non reclutante
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, Stati Uniti, 68046
- Attivo, non reclutante
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, Stati Uniti, 08080
- Attivo, non reclutante
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, Stati Uniti, 13045
- Attivo, non reclutante
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, Stati Uniti, 12553
- Attivo, non reclutante
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, Stati Uniti, 10029
- Attivo, non reclutante
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, Stati Uniti, 28801
- Attivo, non reclutante
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, Stati Uniti, 28054-7489
- Attivo, non reclutante
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, Stati Uniti, 27834-2849
- Reclutamento
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, Stati Uniti, 45801
- Attivo, non reclutante
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, Stati Uniti, 43617
- Attivo, non reclutante
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15241
- Attivo, non reclutante
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, Stati Uniti, 29732
- Attivo, non reclutante
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, Stati Uniti, 30909
- Attivo, non reclutante
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- Attivo, non reclutante
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, Stati Uniti, 79902
- Attivo, non reclutante
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, Stati Uniti, 77090
- Attivo, non reclutante
- Lumi Research - Site Number: 840156
-
Houston, Texas, Stati Uniti, 77099
- Attivo, non reclutante
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, Stati Uniti, 76054
- Attivo, non reclutante
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, Stati Uniti, 77081
- Attivo, non reclutante
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, Stati Uniti, 98225
- Attivo, non reclutante
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
Descrizione
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Lasso di tempo: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Lasso di tempo: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Lasso di tempo: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Lasso di tempo: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Lasso di tempo: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Lasso di tempo: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Lasso di tempo: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Parte 1: Numero di partecipanti caratterizzati dai loro dati demografici e caratteristiche cliniche
Lasso di tempo: Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
|
|
Parte 1: Numero di partecipanti caratterizzati dal loro carico di malattia, stato di salute, esperienze di trattamento
Lasso di tempo: Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
|
|
Parte 1: Numero di partecipanti caratterizzati in base all'uso di farmaci
Lasso di tempo: Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
|
|
Parte 1: Numero di partecipanti caratterizzati dal loro stile di vita e influenze ambientali
Lasso di tempo: Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
|
|
Parte 1: Numero di partecipanti caratterizzato dall’uso di corticosteroidi inalati e sistemici
Lasso di tempo: Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
Parte 1: Da 12 mesi prima dell'arruolamento nello studio
|
|
|
Parte 1: Numero di Partecipanti Caratterizzati dall'Utilizzo delle Risorse Sanitarie (HCRU)
Lasso di tempo: Parte 1: Da 12 mesi precedenti l'arruolamento nello studio
|
Parte 1: Da 12 mesi precedenti l'arruolamento nello studio
|
|
|
Parte 2: Caratterizzazione Descrittiva Inclusi Dati Sociodemografici e Caratteristiche della Malattia e Storia del Trattamento.
Lasso di tempo: Parte 2: Al basale
|
Parte 2: Al basale
|
|
|
Parte 2: Tassi di esacerbazione annualizzati alla settimana 52 e 104
Lasso di tempo: Parte 2: alle settimane 52 e 104
|
Parte 2: alle settimane 52 e 104
|
|
|
Parte 2: Numero di partecipanti analizzati per i cambiamenti nel carico di corticosteroidi inalati e sistemici
Lasso di tempo: Parte 2: Dal basale fino alla settimana 104
|
Parte 2: Dal basale fino alla settimana 104
|
|
|
Parte 2: Variazioni del livello del biomarcatore
Lasso di tempo: Parte 2: Alle settimane 52 e 104
|
Parte 2: Alle settimane 52 e 104
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Lasso di tempo: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Lasso di tempo: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Lasso di tempo: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Lasso di tempo: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Lasso di tempo: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Lasso di tempo: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Lasso di tempo: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Lasso di tempo: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Lasso di tempo: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Lasso di tempo: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
Lasso di tempo: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PIR21191
- 2025-524916-13-00 (Ctis)
- U1111-1336-5183 (Identificatore di registro: ICTRP)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .